In preclinical and clinical studies, cancer treatments often involve the application of recombinant TRAIL or specific monoclonal antibodies targeting TRAIL‐R1 and TRAIL‐R2 to cancer cells effectively. This evidence concerns the gene TNFRSF10A and cancer.